Leukemia Drug Iclusig, Suspended Over Rise in Thromboses, Ready to Re-emerge — Physician’s First Watch
Leukemia Drug Iclusig, Suspended Over Rise in Thromboses, Ready to Re-emerge
By the Editors
The makers of Iclusig (ponatinib) will comply with several FDA-mandated safety measures to address risks for life-threatening thromboses and blood-vessel narrowing, and marketing is expected to resume by the end of January, the FDA said late last week.
The drug, a kinase inhibitor, had been used in chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia before its suspension in late October over "a steady increase in the number of serious vascular occlusion events" in patients.